FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3009250555> ?p ?o ?g. }

• W3009250555 endingPage "58" @default.
• W3009250555 startingPage "49" @default.
• W3009250555 abstract "Prostate cancer remains one of the most actual problems in oncourology due to its high prevalence and resistance to therapy. Within 5 years of active treatment and follow-up, the castration-resistant prostate cancer (CRPC) develops in 10-20% of patients. This type of disease course resists treatments and leads to death. Medical resources distinguish two different forms of CRPC: non-metastatic and metastatic. Such separation is critically important because each of two forms requires different treatment algorithms. This paper summarizes the main outlines of foreign clinical guidelines and reviews the new treatment options for non-metastatic and metastatic CRPC as wells as the design and results of key clinical trials on drug efficiency. To prepare the review, the comprehensive literature search was conducted using PubMed/Medline, the Cochrane Library, EMBASE, CyberLeninka, e-library databases. The search line included phrases containing the following words: prostate cancer, castration-resistant prostate cancer, drug therapy, treatment algorithms, clinical studies, etc. In accordance to foreign guidelines, it is essential to determine the high risk patients with non-metastatic CRPC and promptly apply new therapeutic options including apalutamide and enzalutamide, which have proven being effective in clinical trials as therapies that attenuate the transition of the non-metastatic CRPC to the metastatic stage. Foreign medical guidelines propose to apply a wider set of treatment algorithms for patients with metastatic CRPC, for instance: considerations on possibilities to use the cabazitaxel instead of docetaxel in the 1st line therapy in patients with pre-existing mild peripheral neuropathy, etc. as well as new therapies - pembrolizumab and sipuleucel-T. The issues regarding the selection of patients with CRPC for specific treatment algorithms and defining the optimal sequence of therapeutic regimens as well as combining various regimens with minimizing toxic effects and maximizing patient benefits remain unsolved." @default.
• W3009250555 created "2020-03-13" @default.
• W3009250555 creator A5003615260 @default.
• W3009250555 creator A5005239685 @default.
• W3009250555 creator A5007068111 @default.
• W3009250555 creator A5036625312 @default.
• W3009250555 creator A5056045076 @default.
• W3009250555 creator A5057121551 @default.
• W3009250555 creator A5064393212 @default.
• W3009250555 creator A5070647450 @default.
• W3009250555 creator A5076373358 @default.
• W3009250555 creator A5087639461 @default.
• W3009250555 date "2019-02-15" @default.
• W3009250555 modified "2023-09-23" @default.
• W3009250555 title "CASTRATION-RESISTANT PROSTATE CANCER: NEW PERSPECTIVES IN PHARMACOLOGICAL TREATMENT" @default.
• W3009250555 cites W1498647927 @default.
• W3009250555 cites W1904433804 @default.
• W3009250555 cites W1981713494 @default.
• W3009250555 cites W2055346449 @default.
• W3009250555 cites W2080439368 @default.
• W3009250555 cites W2120292596 @default.
• W3009250555 cites W2123526148 @default.
• W3009250555 cites W2168108459 @default.
• W3009250555 cites W2252849995 @default.
• W3009250555 cites W2489425084 @default.
• W3009250555 cites W2740979023 @default.
• W3009250555 cites W2792086148 @default.
• W3009250555 cites W2795789232 @default.
• W3009250555 doi "https://doi.org/10.18821/0869-2106-2019-25-1-49-58" @default.
• W3009250555 hasPublicationYear "2019" @default.
• W3009250555 type Work @default.
• W3009250555 sameAs 3009250555 @default.
• W3009250555 citedByCount "1" @default.
• W3009250555 countsByYear W30092505552022 @default.
• W3009250555 crossrefType "journal-article" @default.
• W3009250555 hasAuthorship W3009250555A5003615260 @default.
• W3009250555 hasAuthorship W3009250555A5005239685 @default.
• W3009250555 hasAuthorship W3009250555A5007068111 @default.
• W3009250555 hasAuthorship W3009250555A5036625312 @default.
• W3009250555 hasAuthorship W3009250555A5056045076 @default.
• W3009250555 hasAuthorship W3009250555A5057121551 @default.
• W3009250555 hasAuthorship W3009250555A5064393212 @default.
• W3009250555 hasAuthorship W3009250555A5070647450 @default.
• W3009250555 hasAuthorship W3009250555A5076373358 @default.
• W3009250555 hasAuthorship W3009250555A5087639461 @default.
• W3009250555 hasConcept C121608353 @default.
• W3009250555 hasConcept C126322002 @default.
• W3009250555 hasConcept C143998085 @default.
• W3009250555 hasConcept C168563851 @default.
• W3009250555 hasConcept C17744445 @default.
• W3009250555 hasConcept C177713679 @default.
• W3009250555 hasConcept C199539241 @default.
• W3009250555 hasConcept C2776478404 @default.
• W3009250555 hasConcept C2776551883 @default.
• W3009250555 hasConcept C2777899217 @default.
• W3009250555 hasConcept C2778971682 @default.
• W3009250555 hasConcept C2779134260 @default.
• W3009250555 hasConcept C2779473830 @default.
• W3009250555 hasConcept C2780192828 @default.
• W3009250555 hasConcept C2781190966 @default.
• W3009250555 hasConcept C535046627 @default.
• W3009250555 hasConcept C61367390 @default.
• W3009250555 hasConcept C71924100 @default.
• W3009250555 hasConceptScore W3009250555C121608353 @default.
• W3009250555 hasConceptScore W3009250555C126322002 @default.
• W3009250555 hasConceptScore W3009250555C143998085 @default.
• W3009250555 hasConceptScore W3009250555C168563851 @default.
• W3009250555 hasConceptScore W3009250555C17744445 @default.
• W3009250555 hasConceptScore W3009250555C177713679 @default.
• W3009250555 hasConceptScore W3009250555C199539241 @default.
• W3009250555 hasConceptScore W3009250555C2776478404 @default.
• W3009250555 hasConceptScore W3009250555C2776551883 @default.
• W3009250555 hasConceptScore W3009250555C2777899217 @default.
• W3009250555 hasConceptScore W3009250555C2778971682 @default.
• W3009250555 hasConceptScore W3009250555C2779134260 @default.
• W3009250555 hasConceptScore W3009250555C2779473830 @default.
• W3009250555 hasConceptScore W3009250555C2780192828 @default.
• W3009250555 hasConceptScore W3009250555C2781190966 @default.
• W3009250555 hasConceptScore W3009250555C535046627 @default.
• W3009250555 hasConceptScore W3009250555C61367390 @default.
• W3009250555 hasConceptScore W3009250555C71924100 @default.
• W3009250555 hasIssue "1" @default.
• W3009250555 hasLocation W30092505551 @default.
• W3009250555 hasOpenAccess W3009250555 @default.
• W3009250555 hasPrimaryLocation W30092505551 @default.
• W3009250555 hasRelatedWork W122177069 @default.
• W3009250555 hasRelatedWork W179251896 @default.
• W3009250555 hasRelatedWork W2015876133 @default.
• W3009250555 hasRelatedWork W2021751111 @default.
• W3009250555 hasRelatedWork W2135620818 @default.
• W3009250555 hasRelatedWork W2568045406 @default.
• W3009250555 hasRelatedWork W2768688864 @default.
• W3009250555 hasRelatedWork W2773024035 @default.
• W3009250555 hasRelatedWork W3132581442 @default.
• W3009250555 hasRelatedWork W4291017293 @default.
• W3009250555 hasVolume "25" @default.
• W3009250555 isParatext "false" @default.
• W3009250555 isRetracted "false" @default.

• next